Sepulveda-Crespo, DanielYélamos, María BelénDíez, CristinaGómez, JuliánHontañón, VíctorTorresano-Felipe, FranciscoBerenguer, JuanGonzález-García, JuanIbañez-Samaniego, LuisLlop, ElvaOlveira, AntonioMartínez, JavierResino, SalvadorMartinez, Isidoro2022-11-152022-11-152022-06Biomed Pharmacother. 2022 Jun;150:113024.http://hdl.handle.net/20.500.12105/15138Objectives: The current study aimed to assess the impact of HIV on the production of anti-HCV antibodies in HCV-infected individuals with advanced HCV-related cirrhosis before and 36 weeks after the sustained virological response (SVR) induced by direct-acting antivirals (DAAs) therapy. Methods: Prospective study on 62 patients (50 HIV/HCV-coinfected and 12 HCV-monoinfected). Plasma anti-E2 and HCV-nAbs were determined respectively by ELISA and microneutralization assays. Results: At baseline, the HCV-group had higher anti-E2 levels against Gt1a (p = 0.012), Gt1b (p = 0.023), and Gt4a (p = 0.005) than the HIV/HCV-group. After SVR, anti-E2 titers against Gt1a (p < 0.001), Gt1b (p = 0.001), and Gt4a (p = 0.042) were also higher in the HCV-group than HIV/HCV-group. At 36 weeks post-SVR, plasma anti-E2 titers decreased between 1.3 and 1.9-fold in the HIV/HCV-group (p < 0.001) and between 1.5 and 1.8-fold in the HCV-group (p ≤ 0.001). At baseline, the HCV-group had higher titers of HCV-nAbs against Gt1a (p = 0.022), Gt1b (p = 0.002), Gt2a (p < 0.001), and Gt4a (p < 0.001) than the HIV/HCV-group. After SVR, HCV-nAbs titers against Gt1a (p = 0.014), Gt1b (p < 0.001), Gt2a (p = 0.002), and Gt4a (p = 0.004) were also higher in the HCV-group. At 36 weeks post-SVR, HCV-nAbs decreased between 2.6 and 4.1-fold in the HIV/HCV-group (p < 0.001) and between 1.9 and 4.0-fold in the HCV-group (p ≤ 0.001). Conclusions: HIV/HCV-coinfected patients produced lower levels of broad-spectrum anti-HCV antibodies than HCV-monoinfected patients.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Hepatitis CHIVHIV/HCV coinfectionBroad-spectrum neutralizing antibodiesDirect-acting antiviralsHCV clearanceCoinfectionHIV InfectionsHepatitis C, ChronicAntibodies, NeutralizingAntiviral AgentsBroadly Neutralizing AntibodiesHepacivirusHepatitis C AntibodiesHumansLiver CirrhosisProspective StudiesAttribution-NonCommercial-NoDerivatives 4.0 Internacional3548319715011302410.1016/j.biopha.2022.1130241950-6007Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieopen access